Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Assets (2016 - 2025)

Plus Therapeutics has reported Assets over the past 16 years, most recently at $16.3 million for Q4 2025.

  • Quarterly Assets rose 146.12% to $16.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.3 million through Dec 2025, up 146.12% year-over-year, with the annual reading at $16.3 million for FY2025, 146.12% up from the prior year.
  • Assets was $16.3 million for Q4 2025 at Plus Therapeutics, down from $18.7 million in the prior quarter.
  • Over five years, Assets peaked at $24.8 million in Q3 2021 and troughed at $5.6 million in Q1 2024.
  • The 5-year median for Assets is $16.0 million (2023), against an average of $16.1 million.
  • Year-over-year, Assets crashed 64.06% in 2024 and then soared 167.56% in 2025.
  • A 5-year view of Assets shows it stood at $22.0 million in 2021, then increased by 8.58% to $23.9 million in 2022, then plummeted by 52.29% to $11.4 million in 2023, then crashed by 41.75% to $6.6 million in 2024, then soared by 146.12% to $16.3 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Assets are $16.3 million (Q4 2025), $18.7 million (Q3 2025), and $10.4 million (Q2 2025).